We've seen basically an 86% reduction in CRP in obese subjects, and 87%-93% of subjects achieved normalized CRP below 2 milligrams per liter. This is the critical threshold that we believe will correspond to cardiovascular benefits. On the ophthalmology side, therapeutic retinal exposure of our drug enables oral treatment of diseases including diabetic macular edema, where intravitreal anti-IL-6 has shown benefit. We have a very catalyst-rich year. Our cardiovascular risk trial is starting soon and will rea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42279 BIOAGE LABS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4721157 (State or other jurisdiction o ...

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept trial of BGE-102 in cardiovascular risk planned to initiate in mid-2026, with data anticipated by end of year Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema (DME) planned to initiate in mid-2026, with data anticipated in mid-2027 Completed upsized follow-on public offering of $1 ...

事件概述 - BioAge Labs 将于2026年5月8日美国东部时间12:30至14:00举办研发日网络直播 [1] - 活动将聚焦于其新型口服NLRP3炎症小体抑制剂BGE-102的1期临床数据及治疗原理 [1][2] 核心产品BGE-102详情 - BGE-102是一种强效、结构新颖、口服可用、具有潜在同类最佳属性的NLRP3炎症小体抑制剂 [2] - 该候选药物已完成1期单次/多次递增剂量试验 显示出良好的耐受性 并在肥胖和炎症升高的参与者中实现了潜在同类最佳的hsCRP和其他炎症生物标志物降低 [5] - 公司正在开发BGE-102用于治疗动脉粥样硬化性心血管疾病和视网膜疾病 这两种疾病病理均涉及NLRP3驱动的炎症 [2] - BGE-102是一种口服可用、可穿透大脑的小分子NLRP3抑制剂 针对心血管风险和包括糖尿病黄斑水肿在内的视网膜疾病 [5] 研发管线与预期里程碑 - 针对心血管风险的2期概念验证数据预计在2026年下半年获得 [5] - 针对糖尿病黄斑水肿的1b/2a期概念验证数据预计在2027年年中获得 [5] - 公司还在开发用于肥胖症的长效注射和口服小分子APJ激动剂 [5] - 公司的其他临床前项目利用其基于人类长寿数据构建的专有发现平台 针对代谢衰老的关键通路 [5] 专家参与与讨论主题 - 四位领先的学术和临床专家将参与活动并分享观点 [1][3] - Michael Davidson博士将讨论炎症在动脉粥样硬化性心血管疾病中的作用以及心血管风险的新兴治疗方法 [6] - Brian Hafler博士将讨论视网膜疾病中NLRP3介导的炎症 [6] - David Boyer博士将讨论糖尿病黄斑水肿和地图样萎缩领域未满足的临床需求 以及口服抗炎疗法的机遇 [6] - Matthias Geyer博士将讨论NLRP3抑制的结构生物学以及BGE-102差异化作用的分子基础 [6]